{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:13:09Z","timestamp":1784970789129,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bcp.2018.01.043","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T16:35:48Z","timestamp":1517502948000},"page":"291-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments"],"prefix":"10.1016","volume":"151","author":[{"given":"Stephen P.","family":"Arneri\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker D.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane T.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2018.01.043_b0005","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.108.143420","article-title":"Challenges in the search for drugs to treat central nervous system disorders","volume":"329","author":"Enna","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2018.01.043_b0010","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.drudis.2015.02.003","article-title":"An analysis of FDA-approved drugs for neurological disorders","volume":"20","author":"Kinch","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0015","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2018.01.043_b0020","unstructured":"Alzheimer\u2019s Association. 2016-Facts-and-Figures-Fact-Sheet \u2013 Alzheimer\u2019s Association.pdf [Internet]. 2016. Available from: http:\/\/www.alz.org\/documents_custom\/2016-Facts-and-Figures-Fact-Sheet.pdf."},{"key":"10.1016\/j.bcp.2018.01.043_b0025","unstructured":"Institute of Medicine Committee. IOM Biomarkers Recommendations.pdf [Internet]. National Academies Press; Available from: http:\/\/www.nationalacademies.org\/hmd\/~\/media\/Files\/Report%20Files\/2016\/Biomarkers\/Biomarkers-Recs.pdf."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpt.136","article-title":"Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization","volume":"98","author":"Amur","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.01.043_b0035","unstructured":"NCBI NLM NIH. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet] [Internet]. NCBI Bookshelf. 2016. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK338448."},{"key":"10.1016\/j.bcp.2018.01.043_b0040","unstructured":"D.W. Thomas J. Burns J. Audette A. Carroll C. Dow-Hygelund M. Hay, Clinical Development Success Rates 2006-2015 \u2013 BIO Biomedtracker Amplion 2016.pdf [Internet]. Biotechnology Innovation Organization; 2016. Available from: http:\/\/www.businesswire.com\/news\/home\/20160525005693\/en\/BIO-Releases-Largest-Study-Clinical-Development-Success."},{"issue":"5","key":"10.1016\/j.bcp.2018.01.043_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0050","first-page":"491","article-title":"Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention","volume":"95","author":"Trojanowski","year":"2011","journal-title":"Biol. Mark. Neurodegener. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrneurol.2014.232","article-title":"Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases","volume":"11","author":"Lle\u00f3","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0060","doi-asserted-by":"crossref","first-page":"e0147319","DOI":"10.1371\/journal.pone.0147319","article-title":"An Alzheimer\u2019s disease-derived biomarker signature identifies Parkinson\u2019s disease patients with dementia","volume":"11","author":"Berlyand","year":"2016","journal-title":"PLOS ONE"},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer\u2019s disease drug development pipeline","volume":"3","author":"Cummings","year":"2017","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.bcp.2018.01.043_b0075","unstructured":"FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products [Internet]. 2004 Mar p. 38. Available from: https:\/\/www.fda.gov\/scienceresearch\/specialtopics\/criticalpathinitiative\/criticalpathopportunitiesreports\/ucm077262.htm."},{"issue":"9","key":"10.1016\/j.bcp.2018.01.043_b0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0085","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2217\/bmm.15.90","article-title":"Building a roadmap to biomarker qualification: challenges and opportunities","volume":"9","author":"Amur","year":"2015","journal-title":"Biomark. Med."},{"issue":"417","key":"10.1016\/j.bcp.2018.01.043_b0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4599","article-title":"What evidence do we need for biomarker qualification?","volume":"9","author":"Leptak","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2018.01.043_b0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/prca.201000130","article-title":"pathway for qualification of novel methodologies in the European medicines agency","volume":"5","author":"Manolis","year":"2011","journal-title":"Proteom. Clin. Appl."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0100","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.2016.2240","article-title":"Biomarkers and surrogate endpoints: developing common terminology and definitions","volume":"315","author":"Robb","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.59.090506.155819","article-title":"The FDA critical path initiative and its influence on new drug development","volume":"59","author":"Woodcock","year":"2008","journal-title":"Annu. Rev. Med."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0110","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd4435","article-title":"Paving the critical path of drug development: the CDER perspective","volume":"13","author":"Woodcock","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrd4585","article-title":"The European medicines Agency\u2019s strategies to meet the challenges of Alzheimer disease","volume":"14","author":"Haas","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1740774512438980","article-title":"National institute of neurological disorders and stroke common data element project \u2013 approach and methods","volume":"9","author":"Grinnon","year":"2012","journal-title":"Clin. Trial."},{"issue":"22","key":"10.1016\/j.bcp.2018.01.043_b0125","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1089\/neu.2014.3861","article-title":"Pre-clinical traumatic brain injury common data elements: toward a common language across laboratories","volume":"32","author":"Smith","year":"2015","journal-title":"J. Neurotrauma."},{"key":"10.1016\/j.bcp.2018.01.043_b0130","doi-asserted-by":"crossref","unstructured":"R. Willmann J. Dubach K. Chen, Developing standard procedures for pre-clinical efficacy studies in mouse models of spinal muscular atrophy Neuromuscul. Disord. 21 1 74 77.","DOI":"10.1016\/j.nmd.2010.09.014"},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2010.196","article-title":"Motor neuron disease: urgently needed[mdash]biomarkers for amyotrophic lateral sclerosis","volume":"7","author":"Ludolph","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.bcp.2018.01.043_b0140","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2016.07.154","article-title":"Recommended cognitive outcomes in preclinical Alzheimer\u2019s disease: Consensus statement from the European Prevention of Alzheimer\u2019s Dementia project","volume":"13","author":"Ritchie","year":"2017","journal-title":"Alzheim. Dement."},{"issue":"8","key":"10.1016\/j.bcp.2018.01.043_b0145","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer cognitive composite: measuring amyloid-related decline","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol."},{"issue":"16","key":"10.1016\/j.bcp.2018.01.043_b0150","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrd.2017.153","article-title":"Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem","volume":"22","author":"Arneri\u0107","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2018.01.043_b0155","unstructured":"E.R. Dorsey S. Papapetropoulos M. Xiong K. Kieburtz, The First Frontier: Digital Biomarkers for Neurodegenerative Disorders. Digit Biomark [Internet]. 2017 Jul 4 [cited 2017 Sep 14]; Available from: https:\/\/www.karger.com\/?doi=10.1159\/000477383."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154335","article-title":"Remote physical activity monitoring in neurological disease: a systematic review","volume":"11","author":"Block","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bcp.2018.01.043_b0165","unstructured":"A.J. Espay P. Bonato F.B. Nahab W. Maetzler J.M. Dean J. Klucken et al. Technology in Parkinson\u2019s disease: Challenges and opportunities: Technology in PD. Mov Disord [Internet]. 2016 Apr [cited 2016 Aug 18]; Available from: http:\/\/doi.wiley.com\/10.1002\/mds.26642."},{"issue":"9","key":"10.1016\/j.bcp.2018.01.043_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138095","article-title":"Use of High-frequency in-home monitoring data may reduce sample sizes needed in clinical trials","volume":"10","author":"Dodge","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bcp.2018.01.043_b0175","unstructured":"D.J. Conrado M.O. Karlsson K. Romero C. Sarr J.J. Wilkins Open innovation: Towards sharing of data, models and workflows. Eur J Pharm Sci [Internet]. 2017 Jul [cited 2017 Jul 13]; Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717303858."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13311-014-0310-1","article-title":"Commonalities and challenges in the development of clinical trial measures in neurology","volume":"12","author":"Cedarbaum","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0185","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jalz.2014.06.014","article-title":"Alzheimer\u2019s disease public-private partnerships","volume":"10","author":"Snyder","year":"2014","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.bcp.2018.01.043_b0190","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jalz.2015.05.006","article-title":"The impact of the Alzheimer\u2019s Disease Neuroimaging Initiative 2: what role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer\u2019s disease?","volume":"11","author":"Jones-Davis","year":"2015","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1586\/14737175.2015.995637","article-title":"Advances in the therapy of Alzheimer\u2019s disease: targeting amyloid beta and tau and perspectives for the future","volume":"15","author":"Hampel","year":"2015","journal-title":"Expert. Rev. Neurother."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/nm.2221","article-title":"Biomarkers in Alzheimer\u2019s disease drug development","volume":"16","author":"Blennow","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2018.01.043_b0205","first-page":"1","article-title":"Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry","volume":"27","author":"Lewczuk","year":"2017","journal-title":"World J. Biol. Psychiat."},{"issue":"2","key":"10.1016\/j.bcp.2018.01.043_b0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-143006","article-title":"Biomarkers in sporadic and familial Alzheimer\u2019s disease","volume":"47","author":"Lista","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.bcp.2018.01.043_b0215","first-page":"1","article-title":"Blood biomarkers for Alzheimer\u2019s disease: much promise, cautious progress","author":"Keshavan","year":"2016","journal-title":"Mol. Diagn. Ther."},{"issue":"S1","key":"10.1016\/j.bcp.2018.01.043_b0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40120-017-0069-5","article-title":"Increasing precision of clinical diagnosis of Alzheimer\u2019s disease using a combined algorithm incorporating clinical and novel biomarker data","volume":"6","author":"Sabbagh","year":"2017","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.bcp.2018.01.043_b0225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JAD-160573","article-title":"Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: a view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team","volume":"55","author":"Arneric","year":"2017","journal-title":"J. Alzheim. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2018.01.043_b0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jalz.2016.04.001","article-title":"Collaboration for Alzheimer\u2019s prevention: principles to guide data and sample sharing in preclinical Alzheimer\u2019s disease trials","volume":"12","author":"Weninger","year":"2016","journal-title":"Alzheim. Dement."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0235","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/2168479013498386","article-title":"Coalition against major diseases: precompetitive collaborations and regulatory paths to accelerating drug development for neurodegenerative diseases","volume":"47","author":"Stephenson","year":"2013","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2018.01.043_b0240","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jalz.2014.11.005","article-title":"Development of a unified clinical trial database for Alzheimer\u2019s disease","volume":"11","author":"Neville","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bcp.2018.01.043_b0245","unstructured":"J. Neville S. Kopko K. Romero B. Corrigan B. Stafford E. LeRoy et al. Accelerating drug development for Alzheimer\u2019s disease through the use of data standards. Alzheimers Dement Transl Res Clin Interv [Internet]. 2017 Apr [cited 2017 May 4]; Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352873717300239."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0250","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10928-014-9390-0","article-title":"Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop","volume":"41","author":"Romero","year":"2014","journal-title":"J. Pharmacokin. Pharmacodyn."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.07.003","article-title":"Coalition against major diseases\/European medicines agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer\u2019s disease","volume":"10","author":"Hill","year":"2014","journal-title":"Alzheim. Dement"},{"issue":"7","key":"10.1016\/j.bcp.2018.01.043_b0260","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14737175.2016.1194203","article-title":"Analysis of recent failures of disease modifying therapies in Alzheimer\u2019s disease suggesting a new methodology for future studies","volume":"17","author":"Amanatkar","year":"2017","journal-title":"Expert. Rev. Neurother."},{"issue":"5","key":"10.1016\/j.bcp.2018.01.043_b0270","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.01.043_b0275","doi-asserted-by":"crossref","unstructured":"J. McCleery S. Morgan K.M. Bradley A.H. Noel-Storr O. Ansorge C. Hyde Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2015 [cited 2017 Dec 9]. Available from: http:\/\/doi.wiley.com\/10.1002\/14651858.CD010633.pub2.","DOI":"10.1002\/14651858.CD010633.pub2"},{"key":"10.1016\/j.bcp.2018.01.043_b0280","doi-asserted-by":"crossref","unstructured":"N. Mattsson U. Andreasson H. Zetterberg K. Blennow for the Alzheimer\u2019s disease neuroimaging initiative. association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease JAMA Neurol. 2017 74 5 557.","DOI":"10.1001\/jamaneurol.2016.6117"},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13311-016-0503-x","article-title":"Fluid-based biomarkers for amyotrophic lateral sclerosis","volume":"14","author":"Vu","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.bcp.2018.01.043_b0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1871527315666160202121548","article-title":"Novel therapeutic strategies for dementia","volume":"15","author":"Cacabelos","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targ."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13311-016-0484-9","article-title":"Neuroimaging endpoints in amyotrophic lateral sclerosis","volume":"14","author":"Menke","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.01.043_b0300","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/17482960903545334","article-title":"Guidelines for preclinical animal research in ALS\/MND: a consensus meeting","volume":"11","author":"Ludolph","year":"2010","journal-title":"Amyotroph. Lateral. Scler."},{"issue":"19","key":"10.1016\/j.bcp.2018.01.043_b0305","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.0000000000000951","article-title":"The PRO-ACT database Design, initial analyses, and predictive features","volume":"83","author":"Atassi","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.bcp.2018.01.043_b0310","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","article-title":"Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease","volume":"74","author":"Gaiani","year":"2017","journal-title":"JAMA Neurol."},{"issue":"24","key":"10.1016\/j.bcp.2018.01.043_b0315","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","article-title":"Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease","volume":"88","author":"Poesen","year":"2017","journal-title":"Neurology"},{"issue":"45","key":"10.1016\/j.bcp.2018.01.043_b0320","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.1523\/JNEUROSCI.2335-16.2016","article-title":"Current perspectives in autism spectrum disorder: from genes to therapy","volume":"36","author":"Chahrour","year":"2016","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.bcp.2018.01.043_b0325","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/DBP.0000000000000351","article-title":"CONSORTIUM MAS. Phenotyping, etiological factors, and biomarkers: toward precision medicine in autism spectrum disorders","volume":"37","author":"Beversdorf","year":"2016","journal-title":"J. Dev. Behav. Pediatr."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0330","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1474-4422(15)00044-7","article-title":"Gene hunting in autism spectrum disorder: on the path to precision medicine","volume":"14","author":"Geschwind","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2018.01.043_b0335","doi-asserted-by":"crossref","unstructured":"E. Loth W. Spooren D.G. Murphy New treatment targets for autism spectrum disorders: EU-AIMS Lancet Psychiat. 1(6): 413\u2013415.","DOI":"10.1016\/S2215-0366(14)00004-2"},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0340","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd3881","article-title":"EU-AIMS: a boost to autism research","volume":"11","author":"Murphy","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0345","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2015.7","article-title":"Identification and validation of biomarkers for autism spectrum disorders","volume":"15","author":"Loth","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2018.01.043_b0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156624","article-title":"Sex differences in serum markers of major depressive disorder in the netherlands study of depression and anxiety (NESDA)","volume":"11","author":"Ramsey","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bcp.2018.01.043_b0355","unstructured":"A.T. Drysdale L. Grosenick J. Downar K. Dunlop F. Mansouri Y. Meng et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med [Internet]. 2016 Dec 5 [cited 2016 Dec 14]; Available from: http:\/\/www.nature.com\/doifinder\/10.1038\/nm.4246."},{"key":"10.1016\/j.bcp.2018.01.043_b0360","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Orphanet journal of rare diseases","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0365","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","article-title":"Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline?: future clinical trials in HD","volume":"29","author":"Wild","year":"2014","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-160196","article-title":"Cerebrospinal fluid biomarkers for Huntington\u2019s disease","volume":"5","author":"Byrne","year":"2016","journal-title":"J. Huntingt. Dis."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0375","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/mds.26803","article-title":"Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington\u2019s disease: structure Imaging in prodromal HD","volume":"31","author":"Harrington","year":"2016","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bcp.2018.01.043_b0380","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","article-title":"Change in PDE10 across early Huntington disease assessed by [18F] MNI-659 and PET imaging","volume":"86","author":"Russell","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.01.043_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"issue":"2_suppl","key":"10.1016\/j.bcp.2018.01.043_b0390","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1352458516650739","article-title":"The clinical perspective: how to personalise treatment in MS and how may biomarkers including imaging contribute to this?","volume":"22","author":"Vermersch","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.bcp.2018.01.043_b0395","unstructured":"P.M. Matthews, Decade in review [mdash] multiple sclerosis: New drugs and personalized medicine for multiple sclerosis. Nat Rev Neurol [Internet]. 2015 [cited 2016 Nov 30]; Available from: http:\/\/www.nature.com\/nrneurol\/journal\/vaop\/ncurrent\/full\/nrneurol.2015.200.html."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0400","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/2168479013502656","article-title":"The multiple sclerosis outcome assessments consortium: bringing the community together to shape the future of multiple sclerosis drug development","volume":"47","author":"Woodcock","year":"2013","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0405","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Mult. Scler. J."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0410","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1212\/WNL.0000000000000036","article-title":"Assessing treatment response to interferon-\u03b2 is there a role for MRI?","volume":"82","author":"Dobson","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.01.043_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8503859","article-title":"Optical coherence tomography as a biomarker for diagnosis, progression, and prognosis of neurodegenerative diseases","volume":"2016","author":"Satue","year":"2016","journal-title":"J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0420","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.bcp.2018.01.043_b0425","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","article-title":"Time trends in the incidence of parkinson disease","volume":"73","author":"Savica","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcp.2018.01.043_b0430","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/npjparkd.2015.13","article-title":"The range and nature of non-motor symptoms in drug-naive Parkinson\u2019s disease patients: a state-of-the-art systematic review","volume":"1","author":"Zis","year":"2015","journal-title":"Npj Park Dis."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0435","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bcp.2018.01.043_b0440","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease: MDS-PD clinical diagnostic criteria","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0445","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrneurol.2010.52","article-title":"Molecular and clinical prodrome of Parkinson disease: implications for treatment","volume":"6","author":"Schapira","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2018.01.043_b0450","article-title":"Variation in recent onset parkinson\u2019s disease: implications for prodromal detection","author":"Swallow","year":"2016","journal-title":"J. Park Dis."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0455","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker initiative (PPMI)","volume":"95","author":"Marek","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0460","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/mds.26683","article-title":"Biomarkers in Parkinson\u2019s disease: From pathophysiology to early diagnosis: BIOMARKERS IN PD","volume":"31","author":"Calabresi","year":"2016","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0465","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/mds.26635","article-title":"Protein biomarkers in Parkinson\u2019s disease: focus on cerebrospinal fluid markers and synaptic proteins: protein biomarkers in Parkinson\u2019s disease","volume":"31","author":"Halbgebauer","year":"2016","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0470","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression markers initiative study","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol. (Berl)."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0475","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.pneurobio.2011.08.009","article-title":"Imaging biomarkers in Parkinson\u2019s disease","volume":"95","author":"Brooks","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"12","key":"10.1016\/j.bcp.2018.01.043_b0480","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/mds.26290","article-title":"Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson\u2019s disease patients: PLASMA APOA1 and EARLY PD","volume":"30","author":"Swanson","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.01.043_b0485","doi-asserted-by":"crossref","DOI":"10.1002\/mds.26563","article-title":"Serum immune markers and disease progression in an incident Parkinson\u2019s disease cohort (ICICLE-PD)","author":"Williams-Gray","year":"2016","journal-title":"Mov. Disord Off. J. Mov. Disord. Soc."},{"issue":"2","key":"10.1016\/j.bcp.2018.01.043_b0490","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/WAD.0000000000000121","article-title":"Global data sharing in alzheimer disease research","volume":"30","author":"Ashish","year":"2016","journal-title":"Alzheim. Dis. Assoc. Disord."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0495","doi-asserted-by":"crossref","first-page":"160010","DOI":"10.1038\/sdata.2016.10","article-title":"An open access pilot freely sharing cancer genomic data from participants in Texas","volume":"16","author":"Becnel","year":"2016","journal-title":"Sci. Data"},{"issue":"7626","key":"10.1016\/j.bcp.2018.01.043_b0500","doi-asserted-by":"crossref","DOI":"10.1038\/538S4a","article-title":"Perspective: data sharing for discovery","volume":"538","author":"Frasier","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14737175.2015.1002173","article-title":"Alzheimer\u2019s disease: current and future therapy","volume":"15","author":"Stephenson","year":"2015","journal-title":"Exp. Rev. Neurother."},{"key":"10.1016\/j.bcp.2018.01.043_b0510","unstructured":"S. Dubman, Sharing of patient-level data for PD 2016.pdf [Internet]. Call to action: Sharing of patient-level data for Parkinson\u2019s research and care. 2016. Available from: http:\/\/www.journalofparkinsonsdisease.com\/call-action-sharing-patient-level-data-parkinson%E2%80%99s-research-and-care."},{"issue":"10","key":"10.1016\/j.bcp.2018.01.043_b0515","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1474-4422(15)00178-7","article-title":"Diagnosis of Parkinson\u2019s disease on the basis of clinical and genetic classification: a population-based modelling study","volume":"14","author":"Nalls","year":"2015","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.bcp.2018.01.043_b0520","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/gim.2014.55","article-title":"Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants","volume":"16","author":"Alcalay","year":"2014","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0525","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mds.26913","article-title":"Biomarker-driven phenotyping in Parkinson\u2019s disease: a translational missing link in disease-modifying clinical trials: molecular phenotyping For PD","volume":"32","author":"Espay","year":"2017","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0530","doi-asserted-by":"crossref","first-page":"160011","DOI":"10.1038\/sdata.2016.11","article-title":"The mPower study, Parkinson disease mobile data collected using ResearchKit","volume":"3","author":"Bot","year":"2016","journal-title":"Sci. Data."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0535","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/mds.26438","article-title":"The NINDS Parkinson\u2019s disease biomarkers program","volume":"31","author":"Rosenthal","year":"2016","journal-title":"Mov. Disord."},{"issue":"79","key":"10.1016\/j.bcp.2018.01.043_b0540","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002488","article-title":"Biomarkers for Parkinson\u2019s disease","volume":"3","author":"Sherer","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0545","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","article-title":"Advances in markers of prodromal Parkinson disease","volume":"12","author":"Postuma","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.bcp.2018.01.043_b0550","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.01.043_b0555","doi-asserted-by":"crossref","unstructured":"S. Liu F. Zhang X. Wang Y.Y. Shugart Y. Zhao X. Li et al. Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation. Sci Rep [Internet]. 2017 Dec [cited 2017 Dec 8];7(1). Available from: http:\/\/www.nature.com\/articles\/s41598-017-15751-5.","DOI":"10.1038\/s41598-017-15751-5"},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0560","doi-asserted-by":"crossref","first-page":"e1053","DOI":"10.1038\/tp.2017.25","article-title":"New dimensions and new tools to realize the potential of RDoC: digital phenotyping via smartphones and connected devices","volume":"7","author":"Torous","year":"2017","journal-title":"Transl. Psychiat."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0565","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrneurol.2015.30","article-title":"Expert consensus document: mind the gaps[mdash]advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions","volume":"11","author":"Carman","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0570","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrneurol.2013.36","article-title":"Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers","volume":"9","author":"DeKosky","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"04","key":"10.1016\/j.bcp.2018.01.043_b0575","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1055\/s-0032-1331810","article-title":"Advanced neuroimaging in Traumatic brain injury","volume":"32","author":"Edlow","year":"2013","journal-title":"Semin. Neurol."},{"issue":"22","key":"10.1016\/j.bcp.2018.01.043_b0580","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1089\/neu.2013.3306","article-title":"A review of the effectiveness of neuroimaging modalities for the detection of traumatic brain injury","volume":"32","author":"Amyot","year":"2015","journal-title":"J. Neurotrau."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0585","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrneurol.2013.9","article-title":"Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood","volume":"9","author":"Zetterberg","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.bcp.2018.01.043_b0590","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/cns.12127","article-title":"Biomarkers for the clinical differential diagnosis in traumatic brain injury-a systematic review","volume":"19","author":"Yokobori","year":"2013","journal-title":"CNS Neurosci. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0595","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/brainsci7110142","article-title":"Biomarkers associated with the outcome of traumatic brain injury patients","volume":"7","author":"Lorente","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.bcp.2018.01.043_b0600","doi-asserted-by":"crossref","unstructured":"A. Ercole S. Magnoni G. Vegliante R. Pastorelli J. Surmacki S.E. Bohndiek et al. Current and Emerging Technologies for Probing Molecular Signatures of Traumatic Brain Injury. Front Neurol [Internet]. 2017 Aug 30 [cited 2017 Dec 7];8. Available from: http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00450\/full.","DOI":"10.3389\/fneur.2017.00450"},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0605","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.apmr.2010.07.238","article-title":"Common data elements in radiologic imaging of traumatic brain injury","volume":"91","author":"Duhaime","year":"2010","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0610","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.apmr.2010.05.018","article-title":"Common data elements for traumatic brain injury: recommendations from the biospecimens and biomarkers working group","volume":"91","author":"Manley","year":"2010","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"22","key":"10.1016\/j.bcp.2018.01.043_b0615","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1089\/neu.2013.2970","article-title":"Transforming research and clinical knowledge in traumatic brain injury pilot: multicenter implementation of the common data elements for traumatic brain injury","volume":"30","author":"Yue","year":"2013","journal-title":"J. Neurotrau."},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0620","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.apmr.2010.06.033","article-title":"Recommendations for the use of common outcome measures in traumatic brain injury research","volume":"91","author":"Wilde","year":"2010","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0625","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jalz.2015.12.007","article-title":"Inequalities in dementia incidence between six racial and ethnic groups over 14 years","volume":"12","author":"Mayeda","year":"2016","journal-title":"Alzheim. Dement."},{"issue":"6","key":"10.1016\/j.bcp.2018.01.043_b0630","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1504327","article-title":"Incidence of dementia over three decades in the framingham heart study","volume":"374","author":"Satizabal","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.01.043_b0635","doi-asserted-by":"crossref","unstructured":"P. Furlong J.F.P. Bridges L. Charnas J.R. Fallon R. Fischer K.M. Flanigan et al. How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. Orphanet. J. Rare Dis. [Internet]. 2015 Dec [cited 2017 Jan 6];10(1). Available from: http:\/\/www.ojrd.com\/content\/10\/1\/82.","DOI":"10.1186\/s13023-015-0281-2"},{"key":"10.1016\/j.bcp.2018.01.043_b0640","article-title":"Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer\u2019s and Parkinson\u2019s diseases","author":"Ferrari","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"10.1016\/j.bcp.2018.01.043_b0645","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2147\/NDT.S93873","article-title":"Current and emerging treatment strategies for Duchenne muscular dystrophy","volume":"12","author":"Mah","year":"2016","journal-title":"Neuropsychiatr. Dis Treat."},{"issue":"17","key":"10.1016\/j.bcp.2018.01.043_b0650","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0655","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JND-140013","article-title":"Dystrophin analysis in clinical trials","volume":"1","author":"Aartsma","year":"2014","journal-title":"J. Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0660","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.neuron.2014.10.027","article-title":"Medicines for the mind: policy-based \u201cPull\u201d incentives for creating breakthrough CNS drugs","volume":"84","author":"Choi","year":"2014","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.bcp.2018.01.043_b0665","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nn.4429","article-title":"Back to basics: luring industry back into neuroscience","volume":"19","author":"Hyman","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.bcp.2018.01.043_b0670","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/2229-3485.159943","article-title":"Common pitfalls in statistical analysis: clinical versus statistical significance","volume":"6","author":"Ranganathan","year":"2015","journal-title":"Perspect. Clin. Res."},{"issue":"9","key":"10.1016\/j.bcp.2018.01.043_b0675","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jalz.2016.05.005","article-title":"Big data to smart data in Alzheimer\u2019s disease: real-world examples of advanced modeling and simulation","volume":"12","author":"Haas","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.bcp.2018.01.043_b0685","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.trci.2017.08.003","article-title":"Concise informed consent to increase data and biospecimen access may accelerate innovative Alzheimer\u2019s disease treatments","volume":"3","author":"Hake","year":"2017","journal-title":"Alzheim. Dement. Transl. Res. Clin. Interv."},{"issue":"1","key":"10.1016\/j.bcp.2018.01.043_b0690","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","article-title":"Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic","volume":"13","author":"O\u2019Bryant","year":"2017","journal-title":"Alzheim. Dement."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218300492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218300492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T13:54:40Z","timestamp":1668606880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218300492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":137,"alternative-id":["S0006295218300492"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.01.043","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}